A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 17 on September 13, 2024, entitled, "Intraovarian PRP ...

Figure 1. Experimental design scheme for testing the regenerative effects of platelet rich plasma (PRP) in chemotherapy-induced ovarian damage mouse models using CD1 and C57BL/6 strains. Abbreviations ...

CAR-T immune therapies could be effective against solid tumors if the right targets are identified, a new study suggests. The researchers successfully deployed CAR-T in a mouse model of ovarian cancer ...

Serous carcinoma is the most common type of ovarian cancer, accounting for approximately 75% of epithelial ovarian cancers. Cancer treatments are rapidly evolving with the advent of cell therapy.

With the aim of restoring female hormone cycles for pediatric cancer survivors, a team of University of Michigan researchers ...

Hallmarks of a lethal form of ovarian cancer called “high-grade serous ovarian carcinoma” (HGSOC) are an immunosuppressive tumor microenvironment, insensitivity to checkpoint inhibitor immunotherapies ...

Researchers at the Karolinska Institute report CAR T-cell therapy was found to be effective against ovarian cancer in mice. The researchers hope that the discovery will pave the way for a clinical ...

From March 2018 through April 2020, 150 patients received a single infusion of pafolacianine (safety analysis set); 109 patients with folate receptor–positive ovarian cancer comprised the full ...

This study is a collaborative effort led by Dr. Hua Zhang, Dr. Yan Zhang, and Dr. Yuwen Ke from the Department of Zoology and Animal Physiology at the College of Biological Sciences, China ...